Upperton Pharma Solutions’ new pharmaceutical manufacturing facilities in Nottingham have successfully passed inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
 
As part of a planned expansion of its services, Upperton Pharma Solutions, a pharmaceutical contract development and manufacturing organization (CDMO), moved to its new facilities in Nottingham Science and Technology Park from its previous headquarters at BioCity Nottingham in March 2018.
 
The company has made a significant investment in the new facilities for both building enhancements and the expansion of its processing and analytical capabilities.
 
The successful MHRA inspection provides Upperton Pharma Solutions with the necessary MHRA licenses for manufacture, downstream processing into capsules and tablets, as well as release of spray dried formulations of Biotherapeutics and small molecule APIs for clinical trials.
 
The company is also able to now develop pharmaceutical formulations for oral, nasal and pulmonary delivery right through from early feasibility studies to Phases I & II clinical manufacture, from its Nottingham Science and Technology Park site.  
 
Richard Johnson, chief executive officer and founder of Upperton Pharma Solutions, said, “We are absolutely delighted with the expansion of our capabilities in GMP clinical manufacturing and look forward to seeing our clients’ projects progress within Upperton, from early formulation development studies right through to clinical manufacture. The positive endorsement by the MHRA will enable a seamless transition from R&D to GMP manufacture within the organisation, ensuring that all of the project-specific knowledge and expertise developed in R&D will flow through to the GMP manufacturing processes.”